U.S. stocks lower as investors rotate out of tech ahead of Jackson Hole
Smith+Nephew PLC (LSE:SN, NYSE: SNN), a leading global medical technology company with a market capitalization of $11.4 billion, has announced that it will publish its first-quarter trading report for the period ended March 29, 2025, on Wednesday, April 30, 2025. The London-based firm, which specializes in products related to orthopedics, sports medicine, and advanced wound management, will release the report at 7.00 am BST/2.00 am EDT. According to InvestingPro analysis, the company appears undervalued at its current trading price of $25.70, which is near its 52-week low.
Following the release, Smith+Nephew will host a conference call for financial analysts at 8.30 am BST/3.30 am EDT. Details for the call will be made available on the company’s investor relations website. InvestingPro subscribers can access comprehensive financial analysis and additional insights, including multiple ProTips and detailed metrics that suggest strong fundamentals, with the company maintaining a GOOD overall financial health score.
This announcement, contained in a Form 6-K filed with the U.S. Securities and Exchange Commission, outlines Smith+Nephew’s operational updates. The company, founded in 1856, operates in approximately 100 countries and reported annual sales of $5.8 billion in 2024, with a robust gross profit margin of 70.2%. Smith+Nephew is listed on the FTSE100 index, indicating its status as one of the largest companies on the London Stock Exchange (LON:LSEG). The company maintains an impressive 49-year track record of consecutive dividend payments, currently offering a 3.48% yield.
The press release also includes standard forward-looking statements, cautioning that actual results may differ materially from expectations due to various risks and uncertainties. These include market conditions, regulatory actions, product quality, supply chain issues, legal compliance, and competitive factors, among others.
Smith+Nephew’s focus remains on delivering its mission of ’Life Unlimited’ through medical technology that improves patients’ lives. The company employs around 17,000 people worldwide and is committed to innovation across its product portfolio. For detailed analysis and access to the comprehensive Pro Research Report covering Smith+Nephew’s business model, financial health, and growth prospects, visit InvestingPro.
Investors and analysts are directed to the Smith+Nephew website for more information and can reach out to the company’s investor relations contacts for specific inquiries. The information provided in this article is based on the press release statement filed with the SEC.
In other recent news, Smith+Nephew reported strong financial results for 2024, with revenue reaching $5,810 million, up from $5,549 million in 2023, representing an underlying revenue growth of 5.3%. The company also saw a trading profit increase of 8.2% to $1,049 million and an improved operating profit of $657 million, compared to $425 million the previous year. In addition to these results, Smith+Nephew’s fourth quarter revenue was $1,571 million, marking an 8.3% underlying revenue growth. Looking forward, the company anticipates robust revenue growth in 2025, with an expected trading profit margin between 19.0% and 20.0%. Meanwhile, UBS analyst Graham Doyle downgraded Smith+Nephew from Buy to Neutral, citing a revised price target of GBP1.25 and noting the company’s recent stock performance and valuation adjustments. Doyle mentioned that the firm’s earnings per share estimates for 2025 through 2029 are now 3-7% below consensus, leading to a more cautious outlook. These developments come as Smith+Nephew continues to implement its 12-Point Plan aimed at improving productivity and accelerating growth in key areas. The company remains confident in its ability to deliver value to shareholders through ongoing operational improvements and product innovations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.